Simple blood test could help monitor aggressive brain tumors
NCT ID NCT05157594
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at whether a blood test measuring a protein called hPG80 (progastrin) can help track high-grade brain tumors like glioblastoma. Researchers took blood samples from 30 patients before, during, and after radiation and chemotherapy. The goal was to see if hPG80 levels change with tumor progression or treatment, potentially offering a less invasive way to monitor the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a simple blood test to monitor brain tumor progression and response to treatment.
What could go wrong
This is a very small pilot study (30 people) with no control group, so results may not apply broadly. The test is experimental and not yet proven to be reliable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Jean PERRIN
Clermont-Ferrand, 63011, France